S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33

StageZero Life Sciences Stock Forecast, Price & News

0.00 (0.00 %)
(As of 09/24/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Average Volume26,719 shs
Market Capitalization$18.90 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GNWSF News and Ratings via Email

Sign-up to receive the latest news and ratings for StageZero Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

StageZero Life Sciences logo

About StageZero Life Sciences

StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.91 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

StageZero Life Sciences (OTCMKTS:GNWSF) Frequently Asked Questions

Is StageZero Life Sciences a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for StageZero Life Sciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" StageZero Life Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GNWSF, but not buy additional shares or sell existing shares.
View analyst ratings for StageZero Life Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than StageZero Life Sciences?

Wall Street analysts have given StageZero Life Sciences a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but StageZero Life Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has StageZero Life Sciences' stock price been impacted by COVID-19?

StageZero Life Sciences' stock was trading at $0.0266 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GNWSF stock has increased by 1,027.8% and is now trading at $0.30.
View which stocks have been most impacted by COVID-19

Who are StageZero Life Sciences' key executives?

StageZero Life Sciences' management team includes the following people:
  • Mr. James R. Howard-Tripp, Exec. Chairman & CEO
  • Mr. Carl Solomon, Interim Chief Financial Officer
  • Prof. Choong-Chin Liew, Co-Founder
  • Mr. Warren Whitehead C.M.A., Chief Accountant (Age 69)
  • Mr. David Suria, Sr. Scientist

What is StageZero Life Sciences' stock symbol?

StageZero Life Sciences trades on the OTCMKTS under the ticker symbol "GNWSF."

How do I buy shares of StageZero Life Sciences?

Shares of GNWSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is StageZero Life Sciences' stock price today?

One share of GNWSF stock can currently be purchased for approximately $0.30.

How much money does StageZero Life Sciences make?

StageZero Life Sciences has a market capitalization of $18.90 million and generates $4.15 million in revenue each year.

How many employees does StageZero Life Sciences have?

StageZero Life Sciences employs 51 workers across the globe.

What is StageZero Life Sciences' official website?

The official website for StageZero Life Sciences is www.stagezerolifesciences.com.

Where are StageZero Life Sciences' headquarters?

StageZero Life Sciences is headquartered at 70 East Beaver Creek Road Unit 30, Richmond Hill A6, L4B 3B2.

How can I contact StageZero Life Sciences?

StageZero Life Sciences' mailing address is 70 East Beaver Creek Road Unit 30, Richmond Hill A6, L4B 3B2. The company can be reached via phone at 905-209-2030 or via email at [email protected].

This page was last updated on 9/25/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.